{"product_id":"gild-marketing-mix","title":"Gilead Sciences, Inc. (GILD): Marketing Mix Analysis [June-2026 Updated]","description":"\u003cp\u003eThis ready-made late-2025 Marketing Mix Analysis of Gilead Sciences, Inc. gives you a practical, research-based view of how the business sells, reaches, promotes, and prices its portfolio, from Biktarvy’s \u003cstrong\u003e70%\u003c\/strong\u003e U.S. share and Veklury’s revenue role to Livdelzi, Trodelvy, and lenacapavir, plus global access through \u003cstrong\u003e120+\u003c\/strong\u003e countries, a \u003cstrong\u003e17,000+\u003c\/strong\u003e workforce, Foster City operations, a \u003cstrong\u003e$32 billion\u003c\/strong\u003e U.S. buildout, FDA-led launches, PURPOSE 2 and ASCENT-04 messaging, and specialty pricing such as Livdelzi at \u003cstrong\u003e$12,606\u003c\/strong\u003e per 30-day supply.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eGilead Sciences, Inc. - Marketing Mix: Product\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eBiktarvy\u003c\/strong\u003e anchors the HIV franchise, \u003cstrong\u003eLivdelzi\u003c\/strong\u003e adds \u003cstrong\u003e1\u003c\/strong\u003e oral PBC option, \u003cstrong\u003eTrodelvy\u003c\/strong\u003e carries the oncology platform, \u003cstrong\u003elenacapavir\u003c\/strong\u003e moved through \u003cstrong\u003e2\u003c\/strong\u003e phase \u003cstrong\u003e3\u003c\/strong\u003e HIV-prevention trials, and \u003cstrong\u003eVeklury\u003c\/strong\u003e stayed the IV COVID-19 antiviral.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct\u003c\/td\u003e\n\u003ctd\u003eType\u003c\/td\u003e\n\u003ctd\u003eKey numeric facts\u003c\/td\u003e\n\u003ctd\u003eCommercial role\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiktarvy\u003c\/td\u003e\n\u003ctd\u003eOral HIV fixed-dose combination\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e50 mg\u003c\/strong\u003e\/\u003cstrong\u003e200 mg\u003c\/strong\u003e\/\u003cstrong\u003e25 mg\u003c\/strong\u003e; \u003cstrong\u003e1\u003c\/strong\u003e tablet once daily; \u003cstrong\u003e2018\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eHIV treatment flagship\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLivdelzi\u003c\/td\u003e\n\u003ctd\u003eOral liver-disease therapy\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e10 mg\u003c\/strong\u003e once daily; \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePrimary biliary cholangitis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrodelvy\u003c\/td\u003e\n\u003ctd\u003eIV oncology antibody-drug conjugate\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e10 mg\/kg\u003c\/strong\u003e; day \u003cstrong\u003e1\u003c\/strong\u003e and day \u003cstrong\u003e8\u003c\/strong\u003e of \u003cstrong\u003e21\u003c\/strong\u003e-day cycles; \u003cstrong\u003e2020\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eMetastatic breast cancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLenacapavir\u003c\/td\u003e\n\u003ctd\u003eLong-acting HIV capsid inhibitor\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e phase \u003cstrong\u003e3\u003c\/strong\u003e PURPOSE trials; \u003cstrong\u003e927 mg\u003c\/strong\u003e every \u003cstrong\u003e26\u003c\/strong\u003e weeks; \u003cstrong\u003e0\u003c\/strong\u003e infections in PURPOSE \u003cstrong\u003e1\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eHIV prevention and treatment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVeklury\u003c\/td\u003e\n\u003ctd\u003eIV antiviral\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e200 mg\u003c\/strong\u003e on day \u003cstrong\u003e1\u003c\/strong\u003e; \u003cstrong\u003e100 mg\u003c\/strong\u003e daily afterward; \u003cstrong\u003e3\u003c\/strong\u003e-day and \u003cstrong\u003e5\u003c\/strong\u003e-day courses; \u003cstrong\u003e2020\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eCOVID-19 treatment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBiktarvy: \u003cstrong\u003e3\u003c\/strong\u003e active ingredients, \u003cstrong\u003e1\u003c\/strong\u003e tablet, \u003cstrong\u003e1\u003c\/strong\u003e daily dose.\u003c\/li\u003e\n\u003cli\u003eLivdelzi: \u003cstrong\u003e10 mg\u003c\/strong\u003e oral dose, \u003cstrong\u003e1\u003c\/strong\u003e time daily.\u003c\/li\u003e\n\u003cli\u003eTrodelvy: \u003cstrong\u003e10 mg\/kg\u003c\/strong\u003e, \u003cstrong\u003e2\u003c\/strong\u003e infusion days in each \u003cstrong\u003e21\u003c\/strong\u003e-day cycle.\u003c\/li\u003e\n\u003cli\u003eLenacapavir: \u003cstrong\u003e2\u003c\/strong\u003e PURPOSE phase \u003cstrong\u003e3\u003c\/strong\u003e trials, \u003cstrong\u003e26\u003c\/strong\u003e-week dosing interval.\u003c\/li\u003e\n\u003cli\u003eVeklury: \u003cstrong\u003e200 mg\u003c\/strong\u003e start, then \u003cstrong\u003e100 mg\u003c\/strong\u003e maintenance dosing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eBiktarvy\u003c\/h3\u003e\n\u003cp\u003eBiktarvy is a \u003cstrong\u003e3\u003c\/strong\u003e-drug fixed-dose HIV tablet with bictegravir \u003cstrong\u003e50 mg\u003c\/strong\u003e, emtricitabine \u003cstrong\u003e200 mg\u003c\/strong\u003e, and tenofovir alafenamide \u003cstrong\u003e25 mg\u003c\/strong\u003e. The product is taken as \u003cstrong\u003e1\u003c\/strong\u003e tablet once daily and has been part of Gilead Sciences, Inc.'s HIV portfolio since \u003cstrong\u003e2018\u003c\/strong\u003e. Its product design is simple: \u003cstrong\u003e1\u003c\/strong\u003e oral tablet, \u003cstrong\u003e3\u003c\/strong\u003e active agents, and a once-daily schedule.\u003c\/p\u003e\n\n\u003cp\u003eThe combination format matters because it reduces pill count to \u003cstrong\u003e1\u003c\/strong\u003e tablet. In HIV treatment, that makes the product easier to use than multi-pill regimens and keeps it at the center of the company’s HIV mix. The product is also a standard reference point for the rest of the portfolio because it sets the benchmark for oral convenience.\u003c\/p\u003e\n\n\u003ch3\u003eLivdelzi\u003c\/h3\u003e\n\u003cp\u003eLivdelzi is an oral primary biliary cholangitis product with a \u003cstrong\u003e10 mg\u003c\/strong\u003e once-daily dose and a \u003cstrong\u003e2024\u003c\/strong\u003e U.S. approval. It gives Gilead Sciences, Inc. a non-HIV, non-oncology product inside the liver-disease category.\u003c\/p\u003e\n\n\u003cp\u003eThe product’s value is tied to \u003cstrong\u003e1\u003c\/strong\u003e daily oral dose rather than an infusion or injection. For the marketing mix, that places Livdelzi in the same convenience class as chronic oral therapies, which matters in a disease where long-term adherence is important. The approval year also makes it one of the newer additions to the company’s product set.\u003c\/p\u003e\n\n\u003ch3\u003eTrodelvy\u003c\/h3\u003e\n\u003cp\u003eTrodelvy is an IV antibody-drug conjugate dosed at \u003cstrong\u003e10 mg\/kg\u003c\/strong\u003e on day \u003cstrong\u003e1\u003c\/strong\u003e and day \u003cstrong\u003e8\u003c\/strong\u003e of each \u003cstrong\u003e21\u003c\/strong\u003e-day cycle. Its oncology use gives Gilead Sciences, Inc. a product that is structurally different from the HIV and antiviral portfolio because it requires infusion-based administration.\u003c\/p\u003e\n\n\u003cp\u003eTrodelvy was also being advanced in \u003cstrong\u003e1\u003c\/strong\u003est-line triple-negative breast cancer through phase \u003cstrong\u003e3\u003c\/strong\u003e development. The product is already established in metastatic breast cancer settings, so the first-line program matters because it can widen the number of eligible patients. The dosing schedule and IV route make it a higher-touch product than Biktarvy or Livdelzi.\u003c\/p\u003e\n\n\u003ch3\u003eLenacapavir\u003c\/h3\u003e\n\u003cp\u003eLenacapavir is the company’s long-acting HIV capsid inhibitor, built around a \u003cstrong\u003e26\u003c\/strong\u003e-week dosing interval and a \u003cstrong\u003e927 mg\u003c\/strong\u003e subcutaneous dose. In \u003cstrong\u003e2024\u003c\/strong\u003e, the prevention program moved through \u003cstrong\u003e2\u003c\/strong\u003e phase \u003cstrong\u003e3\u003c\/strong\u003e PURPOSE trials, PURPOSE \u003cstrong\u003e1\u003c\/strong\u003e and PURPOSE \u003cstrong\u003e2\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eIn PURPOSE \u003cstrong\u003e1\u003c\/strong\u003e, the lenacapavir arm recorded \u003cstrong\u003e0\u003c\/strong\u003e HIV infections. That number is the clearest product-level milestone in the prevention portfolio because it links the product directly to a long-duration dosing profile. The combination of a \u003cstrong\u003e6\u003c\/strong\u003e-month interval and injectable delivery gives lenacapavir a different product position from daily oral HIV therapy.\u003c\/p\u003e\n\n\u003ch3\u003eVeklury\u003c\/h3\u003e\n\u003cp\u003eVeklury is the company’s IV antiviral for COVID-19, with a regimen of \u003cstrong\u003e200 mg\u003c\/strong\u003e on day \u003cstrong\u003e1\u003c\/strong\u003e and \u003cstrong\u003e100 mg\u003c\/strong\u003e daily after that. The product is used in \u003cstrong\u003e3\u003c\/strong\u003e-day and \u003cstrong\u003e5\u003c\/strong\u003e-day treatment courses, which keeps it structurally different from chronic oral products.\u003c\/p\u003e\n\n\u003cp\u003eThe product remained part of the company’s antiviral mix because it is delivered by infusion and can be used in short treatment courses rather than long-term maintenance. The dose structure is simple and fully numeric: \u003cstrong\u003e200 mg\u003c\/strong\u003e, then \u003cstrong\u003e100 mg\u003c\/strong\u003e, then a course length of \u003cstrong\u003e3\u003c\/strong\u003e or \u003cstrong\u003e5\u003c\/strong\u003e days.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eGilead Sciences, Inc. - Marketing Mix: Place\u003c\/h2\u003e\n\u003cp\u003eAs of late 2025, Gilead Sciences' place strategy centered on a global workforce of \u003cstrong\u003e17,000+\u003c\/strong\u003e, voluntary HIV licenses covering \u003cstrong\u003e120+\u003c\/strong\u003e countries, and a U.S. buildout of \u003cstrong\u003e$32 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eFoster City, California stayed a core hub, and the AI-enabled development center broke ground there.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003ePlace factor\u003c\/th\u003e\n\u003cth\u003eReal-life number or amount\u003c\/th\u003e\n\u003cth\u003eGeographic footprint\u003c\/th\u003e\n\u003cth\u003ePlace effect\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal workforce\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e17,000+\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGlobal\u003c\/td\u003e\n\u003ctd\u003eSupports multi-country operations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVoluntary HIV licenses\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e120+\u003c\/strong\u003e countries\u003c\/td\u003e\n\u003ctd\u003eLicensed territories\u003c\/td\u003e\n\u003ctd\u003eExtends access across a wide international footprint\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. buildout\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$32 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUnited States\u003c\/td\u003e\n\u003ctd\u003eSupports local capacity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore hub\u003c\/td\u003e\n\u003ctd\u003eFoster City, California\u003c\/td\u003e\n\u003ctd\u003eBay Area\u003c\/td\u003e\n\u003ctd\u003eAnchors corporate and development activity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI-enabled development center\u003c\/td\u003e\n\u003ctd\u003eGround broken\u003c\/td\u003e\n\u003ctd\u003eFoster City, California\u003c\/td\u003e\n\u003ctd\u003eAdds future development capacity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e17,000+\u003c\/strong\u003e employees support the operating footprint.\u003c\/li\u003e\n\u003cli\u003eFoster City, California remains the anchor site.\u003c\/li\u003e\n\u003cli\u003eVoluntary HIV licenses reach \u003cstrong\u003e120+\u003c\/strong\u003e countries.\u003c\/li\u003e\n\u003cli\u003eThe U.S. buildout equals \u003cstrong\u003e$32 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe AI-enabled development center adds capacity in Foster City.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e\u003ch2\u003eGilead Sciences, Inc. - Marketing Mix: Promotion\u003c\/h2\u003e\n\u003cp\u003eGilead Sciences, Inc. tied promotion in late 2025 to \u003cstrong\u003eJune 18, 2025\u003c\/strong\u003e, \u003cstrong\u003e2\u003c\/strong\u003e PURPOSE 2 infections in \u003cstrong\u003e2,179\u003c\/strong\u003e participants, a \u003cstrong\u003e35%\u003c\/strong\u003e risk reduction readout in ASCENT-04\/KEYNOTE-D19, and more than \u003cstrong\u003e$260 million\u003c\/strong\u003e in philanthropic grants.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePromotion driver\u003c\/td\u003e\n    \u003ctd\u003eReal-life number\u003c\/td\u003e\n    \u003ctd\u003eReal-life detail\u003c\/td\u003e\n    \u003ctd\u003eLate 2025 promotion use\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eFDA approval\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eJune 18, 2025\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eLenacapavir for HIV pre-exposure prophylaxis\u003c\/td\u003e\n    \u003ctd\u003eLaunch messaging\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eApproved population\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e35 kg\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eAdults and adolescents weighing at least 35 kg\u003c\/td\u003e\n    \u003ctd\u003eTarget audience definition\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePURPOSE 2\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e2,179\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e HIV infections in the lenacapavir arm\u003c\/td\u003e\n    \u003ctd\u003eClinical proof point\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePURPOSE 2 effect\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e96%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eLower HIV risk versus background incidence\u003c\/td\u003e\n    \u003ctd\u003eCore efficacy message\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eASCENT-04\/KEYNOTE-D19\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e35%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eReduction in risk of progression or death\u003c\/td\u003e\n    \u003ctd\u003eOncology promotion\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePhilanthropic grants\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$260 million\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eGrants and charitable support\u003c\/td\u003e\n    \u003ctd\u003ePublic-health reputation\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eFDA approvals anchored product launches\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOn \u003cstrong\u003eJune 18, 2025\u003c\/strong\u003e, the FDA approved lenacapavir for HIV pre-exposure prophylaxis in adults and adolescents weighing at least \u003cstrong\u003e35 kg\u003c\/strong\u003e. The twice-yearly dosing message gave Gilead Sciences, Inc. a promotion platform built around \u003cstrong\u003e2\u003c\/strong\u003e injections a year instead of daily oral PrEP.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n  \u003cli\u003e\n\u003cstrong\u003eJune 18, 2025\u003c\/strong\u003e: FDA approval for HIV pre-exposure prophylaxis\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e35 kg\u003c\/strong\u003e: minimum approved body weight for adolescents\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e: dosing frequency per year\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003ePURPOSE 2 data lifted lenacapavir profile\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePURPOSE 2 included \u003cstrong\u003e2,179\u003c\/strong\u003e participants and recorded \u003cstrong\u003e2\u003c\/strong\u003e HIV infections in the lenacapavir arm. The study showed a \u003cstrong\u003e96%\u003c\/strong\u003e lower HIV risk versus background incidence, which gave Gilead Sciences, Inc. a simple data point for medical and public-health promotion.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eASCENT-04 data supported Trodelvy messaging\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eASCENT-04\/KEYNOTE-D19 was a phase \u003cstrong\u003e3\u003c\/strong\u003e study in first-line PD-L1-positive metastatic triple-negative breast cancer. The data package included a \u003cstrong\u003e35%\u003c\/strong\u003e reduction in risk of progression or death, which strengthened oncology promotion for sacituzumab govitecan.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGenesis AI partnership signaled R\u0026amp;D innovation\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGilead Sciences, Inc. kept Genesis Therapeutics in the promotion mix as an AI-based R\u0026amp;D signal in late 2025. The collaboration message linked external innovation with pipeline development, even without a public product launch number attached to it.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePhilanthropic grants topped $260 million\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGilead Sciences, Inc. reported more than \u003cstrong\u003e$260 million\u003c\/strong\u003e in philanthropic grants and charitable support. That number supported promotion around access, community health, and disease awareness.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n  \u003cli\u003e\n\u003cstrong\u003e2,179\u003c\/strong\u003e participants in PURPOSE 2\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e infections in the lenacapavir arm\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e96%\u003c\/strong\u003e lower HIV risk in PURPOSE 2\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e35%\u003c\/strong\u003e reduction in progression or death in ASCENT-04\/KEYNOTE-D19\u003c\/li\u003e\n  \u003cli\u003eMore than \u003cstrong\u003e$260 million\u003c\/strong\u003e in philanthropic grants\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e\u003ch2\u003eGilead Sciences, Inc. - Marketing Mix: Price\u003c\/h2\u003e\n\u003cp\u003eGilead Sciences, Inc. set Livdelzi at \u003cstrong\u003e$12,606\u003c\/strong\u003e per \u003cstrong\u003e30-day supply\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e$12,606\u003c\/strong\u003e x \u003cstrong\u003e12\u003c\/strong\u003e = \u003cstrong\u003e$151,272\u003c\/strong\u003e per year.\u003c\/p\u003e\n\u003cp\u003eHIV voluntary licenses covered \u003cstrong\u003e6\u003c\/strong\u003e generic manufacturers and \u003cstrong\u003e120\u003c\/strong\u003e countries.\u003c\/p\u003e\n\u003cp\u003eThe DOJ and HHS PrEP patent arrangement involved \u003cstrong\u003e2\u003c\/strong\u003e federal agencies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n  \u003cli\u003e\n\u003cstrong\u003e$12,606\u003c\/strong\u003e per \u003cstrong\u003e30-day supply\u003c\/strong\u003e for Livdelzi\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e$151,272\u003c\/strong\u003e annualized at \u003cstrong\u003e12\u003c\/strong\u003e fills\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e6\u003c\/strong\u003e generic manufacturers under HIV voluntary licenses\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e120\u003c\/strong\u003e countries covered by HIV voluntary licenses\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e federal agencies in the DOJ\/HHS PrEP patent arrangement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePrice item\u003c\/td\u003e\n    \u003ctd\u003eAmount\u003c\/td\u003e\n    \u003ctd\u003eUnit\u003c\/td\u003e\n    \u003ctd\u003eCoverage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eLivdelzi\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$12,606\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e30-day supply\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e$151,272\u003c\/strong\u003e per 12 fills\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eHIV voluntary licenses\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e6\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003egeneric manufacturers\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e120\u003c\/strong\u003e countries\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDOJ\/HHS PrEP patent arrangement\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003efederal agencies\u003c\/td\u003e\n    \u003ctd\u003efuture PrEP patent licenses\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44602219397269,"sku":"gild-marketing-mix","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/gild-marketing-mix.png?v=1740177775","url":"https:\/\/dcf-model.com\/products\/gild-marketing-mix","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}